Regulatory Forum Opinion Piece*-Reference-Cited by-同舟云学术

Regulatory Forum Opinion Piece*

Published:2015-01-27 Issue:5 Volume:43 Page:605-610
ISSN:0192-6233
Container-title:Toxicologic Pathology
language:en
Short-container-title:Toxicol Pathol

Author:

Jacobs Abigail C.¹,Brown Paul C.¹

Affiliation:

1. Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA

Abstract

The International Conference on Harmonization (ICH; S1B of 1997) allows a second species carcinogenicity study to be an alternative to one of the traditional 2-year studies. In the past 17 years, the FDA’s Center for Drug Evaluation and Research’s (CDER) Executive Carcinogenicity Assessment Committee received 269 alternative carcinogenicity assay protocols for review. This committee’s recommendations regarding choice of animal model and dose selection are generally followed by sponsors conducting these studies to increase the acceptability of such studies. The P53+/− assay is generally considered appropriate for genotoxic products, and the TgRasH2 assay is appropriate for non-genotoxic or genotoxic drugs. In the United States, the TgAC assay is not used any more and the animals are no longer available. The TgAC assay can detect both tumor promoters and complete carcinogens, and consequently more than half of the dermal TgAC assays resulted in a positive assessment. Currently, more than 75% of mouse carcinogenicity studies are conducted in TgRasH2 mice. Behavior of genotoxic and non-genotoxic drugs in the various assays is reviewed.

Publisher

SAGE Publications

Subject

Cell Biology,Toxicology,Molecular Biology,Pathology and Forensic Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/0192623314566241

Reference6 articles.

1. Phenolphthalein Induces Thymic Lymphomas Accompanied by Loss of the p53 Wild Type Allele in Heterozygous p53-Deficient (±) Mice

2. FDA (Food and Drug Administration). (1999). Removal of phenolphthalein from the market, 21CFR Part 310 [Docket No. 78N-036L] RIN 0910-AA01 Laxative Drug Products for Over-the-Counter Human Use AGENCY: Food and Drug Administration http://www.fda.gov/ohrms/dockets/98fr/012999d.txt, HHS. ACTION: Final rule. EFFECTIVE DATE: January 29, 1999.

3. ICH (International Conference on Harmonization). (1997). International harmonization of pharmaceutical requirements: Guidance for industry: S1B testing for carcinogenicity of pharmaceuticals. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm065007.htm.

4. National Toxicology Program. (1996). Toxicology and Carcinogenesis Studies of Phenolphthalein in F344/N Rats and B6C3F1 Mice (Feed Studies). NTP TR. 465, NIH Publication no.97-3390, Research Triangle Park, NC.

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering exogenous chemical carcinogenicity through interpretable deep learning: A novel approach for evaluating atmospheric pollutant hazards;Journal of Hazardous Materials;2024-03

2. Review of machine learning and deep learning models for toxicity prediction;Experimental Biology and Medicine;2023-12-06

3. DCAMCP: A deep learning model based on capsule network and attention mechanism for molecular carcinogenicity prediction;Journal of Cellular and Molecular Medicine;2023-07-31

4. Pathophysiology and human cancer risk assessment of pharmaceutical-induced thymoma in carcinogenicity studies;Toxicology and Applied Pharmacology;2023-05

5. Animal use and opportunities for reduction in carcinogenicity studies supporting approved new drug applications in the U.S., 2015–2019;Regulatory Toxicology and Pharmacology;2023-01